With the novel peptide KCF18, this study managed to achieve simultaneous inhibitions of TNF-α, IL-1β, and IL-6 and thus can compare the therapeutic effects of triple versus single cytokine inhibitions against endotoxemia. This evidence concerns the gene IL1B and serum lipopolysaccharide activity.